# Small Cell Lung Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/small-cell-lung-cancer

> 12 upcoming FDA catalysts in small Cell Lung Cancer: IMDELLTRA® (tarlatamab, AMGN) on Sep to Dec 2027 (topline data readout); IMDELLTRA® (tarlatamab, AMGN) on September 2027 (primary completion); KEYTRUDA® (pembrolizumab, MRK) on Oct 2027 to Jan 2028 (topline data readout); alisertib (PBYI) on Oct 2027 to Jan 2028 (topline data readout); and 8 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 23, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Small Cell Lung Cancer | completed | "NCT04924101 (Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-23 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-07-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04924101)) |
| July 1, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Small Cell Lung Cancer | completed | "NCT04924101 (Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-23 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-07-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04924101?tab=results)) |
| Sep to Dec 2027 | [IMDELLTRA® (tarlatamab) topline data readout](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Small Cell Lung Cancer | scheduled | "NCT07778316 (Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07778316)) |
| September 2027 | [IMDELLTRA® (tarlatamab) primary completion](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Small Cell Lung Cancer | scheduled | "NCT07778316 (Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07778316)) |
| Oct 2027 to Jan 2028 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Small Cell Lung Cancer | scheduled | "NCT04624204 (Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04624204)) |
| Oct 2027 to Jan 2028 | [Alisertib topline data readout](https://sec-api.dev/pdufa/alisertib) | PBYI | Small Cell Lung Cancer | scheduled | "NCT06095505 (A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-30 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06095505)) |
| October 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Small Cell Lung Cancer | scheduled | "NCT04624204 (Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04624204)) |
| October 2027 | [Alisertib primary completion](https://sec-api.dev/pdufa/alisertib) | PBYI | Small Cell Lung Cancer | scheduled | "NCT06095505 (A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-30 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06095505)) |
| Jun to Sep 2028 | [ZL-1310 topline data readout](https://sec-api.dev/pdufa/zl-1310) | ZLAB | Small-cell Lung Cancer | scheduled | "NCT07218146 (A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Zai Lab (Shanghai) Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218146)) |
| June 2028 | [ZL-1310 primary completion](https://sec-api.dev/pdufa/zl-1310) | ZLAB | Small-cell Lung Cancer | scheduled | "NCT07218146 (A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Zai Lab (Shanghai) Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218146)) |
| April 2029 | [ABBV-706 primary completion](https://sec-api.dev/pdufa/abbv-706) | ABBV | Small Cell Lung Cancer | scheduled | "NCT07155174 (A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07155174)) |
| Apr to Jul 2029 | [ABBV-706 topline data readout](https://sec-api.dev/pdufa/abbv-706) | ABBV | Small Cell Lung Cancer | scheduled | "NCT07155174 (A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07155174)) |
| September 2030 | [ABBV-706 primary completion](https://sec-api.dev/pdufa/abbv-706) | ABBV | Small Cell Lung Cancer | scheduled | "NCT07365241 (A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365241)) |
| Sep to Dec 2030 | [ABBV-706 topline data readout](https://sec-api.dev/pdufa/abbv-706) | ABBV | Small Cell Lung Cancer | scheduled | "NCT07365241 (A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365241)) |

## Drugs

- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [IMDELLTRA® (tarlatamab)](https://sec-api.dev/pdufa/tarlatamab) (AMGN)
- [Alisertib](https://sec-api.dev/pdufa/alisertib) (PBYI)
- [ZL-1310](https://sec-api.dev/pdufa/zl-1310) (ZLAB)
- [ABBV-706](https://sec-api.dev/pdufa/abbv-706) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/small-cell-lung-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Small Cell Lung Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/small-cell-lung-cancer

```bibtex
@misc{secapidev_indications_small_cell_lung_cancer_20261116,
  title        = {Small Cell Lung Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/small-cell-lung-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_small_cell_lung_cancer_20261116","title":"Small Cell Lung Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/small-cell-lung-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
